Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Protagonist Therapeutics ...

    NASDAQ: PTGX · Real-Time Price · USD
    44.31
    -1.20 (-2.64%)
    At close: May 05, 2025, 3:59 PM
    44.28
    -0.07%
    After-hours: May 05, 2025, 04:43 PM EDT
    -2.64%
    Bid 43.49
    Market Cap 2.72B
    Revenue (ttm) 434.43M
    Net Income (ttm) 275.19M
    EPS (ttm) 4.23
    PE Ratio (ttm) 10.48
    Forward PE -44.71
    Analyst Buy
    Ask 47.34
    Volume 436,454
    Avg. Volume (20D) 1,236,926
    Open 45.12
    Previous Close 45.51
    Day's Range 44.18 - 45.48
    52-Week Range 25.23 - 60.60
    Beta 2.29

    About PTGX

    Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Aug 11, 2016
    Employees 126
    Stock Exchange NASDAQ
    Ticker Symbol PTGX
    Website https://www.protagonist-inc.com
    Full Company Profile

    Analyst Forecast

    According to 9 analyst ratings, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 46.69% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Protagonist Therapeutics Inc. is scheduled to release its earnings on May 16, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +45.89%
    Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription
    2 months ago
    +2.42%
    Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.
    news image

    1 week ago · accessnewswire.com

    Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

    NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the A...

    news image

    2 weeks ago · accessnewswire.com

    Protagonist Therapeutics Reports Granting of Inducement Award

    NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

    news image

    1 month ago · zacks.com

    Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

    The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

    news image

    1 month ago · accessnewswire.com

    Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

    Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical...

    news image

    1 month ago · zacks.com

    Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

    Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · seekingalpha.com

    Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

    Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotr...

    news image

    1 month ago · zacks.com

    PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

    The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

    1 month ago · youtube.com

    Overlooked Stock: PTGX

    Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock,...

    news image

    1 month ago · investors.com

    Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

    Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out...

    news image

    1 month ago · benzinga.com

    Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

    On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).

    Add to Watchlist